Vivlion

Executive Summary

Vivlion, a German biotechnology company founded in 2020, is advancing drug target discovery through its proprietary PRCISR™ technology, which enables the production of highly uniform CRISPR sgRNA libraries for efficient screening. By offering both ready-to-use libraries and comprehensive screening services, Vivlion accelerates R&D pipelines in academia and industry. The company's platform addresses a critical bottleneck in functional genomics: the need for precise, reproducible screening tools to identify novel drug targets. Despite being early-stage, Vivlion's focus on CRISPR-based solutions positions it within a rapidly growing market, leveraging synthetic biology and genetics. The company has not disclosed funding or valuation, suggesting a pre-revenue or nascent commercial stage. However, its technology has the potential to streamline drug discovery, making it a compelling player in the gene-editing ecosystem.

Upcoming Catalysts (preview)

• TBDLaunch of new CRISPR library for oncology targets60% success
• TBDStrategic partnership with major pharmaceutical company40% success
• TBDSeries A funding round closing50% success